Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Aplastic anemia not responsive to immunosuppressive therapy * Metastatic renal cell carcinoma * Hematologic malignancy, including any of the following: * Acute myeloid leukemia (AML)\* not curable with chemotherapy and meeting any of the following criteria: * AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive \[Ph+\]) * AML evolved from prior myelodysplasia * AML secondary to prior chemotherapy * Failed to achieve remission * In second or subsequent remission NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy * Myelodysplasia\* with any of the following high-risk features: * Adverse cytogenetics (-7, 7q, -5, -5q, complex) * Excess blasts * Prior conversion to AML * Severe cytopenias with absolute neutrophil count \< 500/mm\^3 or platelet count \< 20,000/mm\^3 NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy * Acute lymphoblastic leukemia (ALL)\* not curable with chemotherapy and meeting any of the following criteria: * High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7) * More than 1 induction course required to achieve remission * Failed to enter remission * In second or subsequent remission NOTE: \*Marrow blasts \< 10 % * Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following: * Refractory to initial or subsequent therapy * Progression after initial response to therapy * Prolymphocytic morphology * Follicular lymphoma with any of the following high-risk features: * Refractory to initial or subsequent therapy * Progression after response to initial therapy * Has ≥ 3 International Prognostic Index (IPI) risk factors * Multiple myeloma * Stage II-III disease confirmed at diagnosis or after initial progression * Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following: * Diffuse large cell lymphoma * Mantle cell lymphoma * Hodgkin's lymphoma * Myeloproliferative disease with evidence of disease acceleration, including any of the following: * Myelofibrosis * Polycythemia vera * Essential thrombocythemia * Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate * Disease must be stable or responding to therapy * No rapid progression of malignant disease * Expected time to disease progression \> 12 weeks * Not eligible for autologous stem cell transplantation * Matched unrelated donor available * 9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ PATIENT CHARACTERISTICS: * Creatinine \< 2.0 mg/dL * Creatinine clearance \> 40 mL/min * Bilirubin \< 3 mg/dL * Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal * AST \< 4 times upper limit of normal * Hepatitis C or B allowed provided bilirubin and AST are normal * Cardiac ejection fraction \> 30% * DLCO \> 40% of predicted * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No uncontrolled active infection requiring ongoing antibiotic treatment * No poor performance status * No poor organ function PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior stem cell or bone marrow transplantation allowed